FTC conditionally approves generic pharma merger

ANI Pharmaceuticals must divest the production rights for a generic antibiotic and a generic steroid to proceed with its $210 million purchase of Novitium, the Federal Trade Commission has said.


Get unlimited access to all Global Competition Review content